gms | German Medical Science

Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

15.09. - 18.09.2021, virtuell

Article

Send article

Influence of smoking status on clinical and radiological effect of rituximab in patients with rheumatoid arthritis

Meeting Abstract

Search Medline for

  • Anastasia Kudryavtseva - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Galina Lukina - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Eugenia Aronova - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Galina Gridneva - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Svetlana Glukhova - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Aleksander Smirnov - V.A. Nasonova Research Institute of Rheumatology, Moscow

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). sine loco [digital], 15.-18.09.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocRA.52

doi: 10.3205/21dgrh133, urn:nbn:de:0183-21dgrh1335

Published: September 14, 2021

© 2021 Kudryavtseva et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Introduction: Given the availability of data on the negative effect of smoking on the course of rheumatoid arthritis (RA), to assess the effectiveness of rituximab therapy (RTM) depending on smoking status.

Methods: 197 nonsmokers and 31 smokers with RA were included in the study. The main parameters, such as disease activity, main clinical and immunological characteristics, the groups did not differ statistically: the average activity according to the DAS28 index in the group of smoking patients was 5.93 ± 1.10, non-smokers - 5.95 ± 1.21. The clinical effect was assessed according to the EULAR criteria, the radiological assessment was assessed by the Sharp method in the Van der Heide modification at 0 and 48 weeks.

Results: After 48 weeks, when analyzing the clinical response in the groups, there was a similar response to RTM therapy regardless of smoking status: in the group of non-smoking patients DAS28-4.55 ± 1.7, smokers DAS28-4.41 ± 1.51 (p> 0.05). When assessing the radiological effect of RTM at 48 weeks, depending on smoking status, the results were also similar: in the group of nonsmokers, no progression in terms of the total score was noted in 61.97%, and in the group of smokers - in 58.33% of patients, no progression in account of erosion - in the non-smoking group - 73.24% of patients, in the group of smokers - 83.33%, due to the narrowing of the joint spaces - non-smokers - 67.67%, and smokers - 58.33% of patients (p> 0.05). When assessing the dynamics of X-ray progression - the delta of the total score according to Sharpe - there was a tendency towards greater progression in the group of smoking patients - the average delta of the total score was 8.0 ± 11.45, and in the non-smoking group - 6.09 ± 14.3, however, these differences did not reach statistically significant values.

Conclusion: Thus, the obtained data show that smoking status does not affect the clinical efficacy of RTM and is not a factor influencing the manifestation of X-ray inhibition in patients with RA.

Disclosures: None declared